NSCLC
Conditions
Keywords
Brain metastasis, Apatinib, Radiotherapy, NSCLC, Drive gene negative
Brief summary
The purpose of this study is to evaluate the efficacy and safety of concurrent radiotherapy with Apatinib in patients with Brain Metastases from drive gene wide-type Non-small-cell Lung Cancer (NSCLC).
Detailed description
Brain metastases (BM) develop in 22-54% of NSCLC patients during the disease course. NSCLC patients with BM with a median overall survival (OS) of 2-3 months when treated with systemic corticosteroid alone, and a median OS of 3-6 months when treated with whole brain radiation therapy (WBRT). Recently, several studies have reported the benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for EGFR mutation NSCLC patients with BM. The median OS of EGFR mutation patients with BM significantly improved with TKIs treatment, which ranged from 11.8 to 18.8 months. However, for the EGFR wide-type NSCLC patients with BM, the prognosis remains poor. It was found that the combination of anti-VEGF drugs and brain radiotherapy can not only reduce the volume of peritumoral brain edema (PTBE), reduce the intracranial pressure, relieve the symptoms of nerve compression, reduce the risk of brain hernia during brain radiotherapy, and but also inhibit the hypoxia of tumor cells, increase the radiosensitivity of tumor cells, and ultimately improve the efficacy of radiotherapy. Apatinib, a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor (VEGFR) and mildly inhibits c-Kit and c-SRC, has been reported to show efficacy among some patients with malignant supratentorial gliomas. Therefore, the investigators initiated this study to evaluate the efficacy and safety of concurrent radiotherapy with Apatinib in patients with Brain Metastases from drive gene wide-type Non-small-cell Lung Cancer (NSCLC).
Interventions
DRUGApatinib
radiotherapy with Apatinib
Sponsors
Hubei Cancer Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18-75 years old, male or female, signed informed consent; 2. The primary lesion is confirmed by histopathology. The patient with brain metastases confirmed by histopathology or imaging confirmed the brain metastases. All patients with non-small cell lung cancer brain metastases should be recommended for EGFR mutation and ALK gene rearrangement assay，exclusion of patients with NSCLC brain metastases with positive EGFR-sensitive mutations and ALK gene rearrangement detection for TKI treatment; After multidisciplinary consultation and evaluation, patients with single or local multiple metastatic tumors with well-controlled primary lesions, who have the economic ability and are willing to undergo surgery for brain metastatic tumors were excluded. 3. Observable imaging data such as CT, MRI, etc., have measurable lesions as defined by RECIST 1.1 (R09-0262); 4. ECOG PS score: 0-2; 5. Hemogram index: RBC≥3.0×1012/L, WBC≥3.5×109/L, ANC≥1.5×109/L, PLT≥100×109/L, Hb≥90g/L 6. the expected survival time ≥ 3 months 7. Renal function: Cr≤1.2×UNL (upper limit of normal value); 8. Liver function: total bilirubin ≤ 1.5 × UNL; ALT, AST ≤ 1.5 × UNL
Exclusion criteria
1. . Allergies, known to be hypersensitive to any excipients in the study drug. ; 2. . Patients with recurrent brain metastases have previously received brain radiation therapy 3. . Patients with high fever and acute infection; 4. . Patients with active, progressive bleeding or a significant bleeding tendency in the primary lesion; 5. . Participated in any clinical trial of research drugs within 4 weeks prior to enrollment 6. . Diarrhea is the main symptom of the important or newly diagnosed acute gastrointestinal diseases, such as Crohn's disease, malabsorption or any cause of CTC ≥ 2 grade diarrhea. 7. . Current clinically relevant cardiovascular disease or medical history, such as refractory hypertension, NYHA grade 3 congestive heart failure, unstable angina or poorly controlled arrhythmias. Myocardial infarction occurred 6 months before randomization. 8. . Absolute neutrophil count \<1000/mm3; 9. . Platelet count \<50000/mm3; 10. . According to the investigator's point of view, any other serious disease or organ system dysfunction that may affect patient safety or interfere with the safety assessment of the test drug, such as proteinuria (CTCAE4.0-≥3), severe liver and kidney dysfunction (CTCAE4.0-≥3), hand-foot syndrome (CTCAE4.0-≥3) and so on. 11. . There are ulcers, intestinal perforations, and intestinal obstruction. 12. . Pregnant and lactating women 13. . Suspected or indeed have a history of alcohol and drug abuse
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Intracranial progression-free survival (iPFS) | Evaluated in 24 months since the treatment began | Defined as the time from randomisation to progression of intracranial disease or death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate (DCR) | 4 weeks after Radiotherapy. | Proportion of patients with reduction or keeping in stable in tumor burden of a predefined amount |
| Objective response rate (ORR) | 4 weeks after Radiotherapy. | Proportion of patients with reduction in tumor burden of a predefined amount |
| intracranial time to progress (ITTP) | Tumor assesment at 4 weeks and 12 weeks after radiotherapy, and then every 12 weeks, up to 24 months | Defined as the time from randomisation to progression of intracranial disease |
| Overall survival (OS) | Tumor assesment at 4 weeks and 12 weeks after radiotherapy, and then every 12 weeks, up to 24 months | Defined as the time from randomisation to death from any cause |
| Rate of Peritumoalbrainedema (PTBE) | 4 weeks after Radiotherapy. | PTBE volume was measured in a similar manner by measuring the high SI region in T2WI that was clearly distinguished from normal tissues, including the tumor. Edema index was calculated by dividing the PTBE volume by tumor volume. The Edema index represents the degree of the PTBE, compared to tumor volume, with an index of 1.0 indicating no PTBE development. |
Countries
China
Outcome results
None listed